Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice

Bouchenaki, Hichem; Danigo, Aurore; Bernard, Amandine; Bessaguet, Flavien; Richard, Laurence; Sturtz, Franck; Balayssac, David; Magy, Laurent; Demiot, Claire

doi:10.3389/fphar.2021.712442

Cited by 9 publications

(8 citation statements)

References 60 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tactile sensitivity was assessed using the von Frey filament test (Bioseb, France) [ 71 ]. Mice were placed in a plastic cage with a wire mesh floor, which allowed access to their paws for 30 min for acclimatization.…”

Section: Methodsmentioning

confidence: 99%

Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice

Bernard,

Mroué,

Bourthoumieu

et al. 2024

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

Among the vinca-alkaloid class, vincristine is a potent chemotherapeutic agent with significant neurotoxic effects and is employed to address a wide spectrum of cancer types. Recently, the therapeutic potential of the cholecystokinin type 2 receptor (CCK2R) as a target for vincristine-induced peripheral neuropathy (VIPN) was demonstrated. In this study, the impact of preventive CCK2R blockade using netazepide (Trio Medicines Ltd., London, UK) was investigated in a mouse model of vincristine-induced peripheral neuropathy. Netazepide is a highly selective CCK2R antagonist under development for the treatment of patients with gastric neuroendocrine tumors caused by hypergastrinemia secondary to chronic autoimmune atrophic gastritis. Vincristine-induced peripheral neuropathy was induced by intraperitoneal injections of vincristine at 100 µg/kg/d for 7 days (D0 to D7). Netazepide (2 mg/kg/d or 5 mg/kg/d, per os) was administered one day before vincristine treatment until D7. Vincristine induced a high tactile allodynia from D1 to D7. VIPN was characterized by dorsal root ganglion neuron (DRG) and intraepidermal nerve fiber (IENF) loss, and enlargement and loss of myelinated axons in the sciatic nerve. Netazepide completely prevented the painful symptoms and nerve injuries induced by vincristine. In conclusion, the fact that netazepide protected against vincristine-induced peripheral neuropathy in a mouse model strongly supports the assessment of its therapeutic potential in patients receiving such chemotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice

Bernard,

Mroué,

Bourthoumieu

et al. 2024

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mouse models of CIPN were established by intraperitoneal injections as detailed below ( Figure 1 ): VCR-induced peripheral neuropathy; one daily injection of VCR (100 µg/kg) every day over 7 days [ 17 ]. OXP-induced peripheral neuropathy; one daily injection of OXP (6 mg/kg), every three days over 6 days [ 18 ]. …”

Section: Methodsmentioning

confidence: 99%

Neuroprotective Effect of Polyvalent Immunoglobulins on Mouse Models of Chemotherapy-Induced Peripheral Neuropathy

Mroué,

Bessaguet,

Nizou

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

The occurrence of neuropathic pain in chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting effect of many commonly-used anticancer agents. Polyvalent human immunoglobulins (hIg), used in the treatment of several peripheral neuropathies, may alleviate neuropathic pain. The aim of this project was to investigate the preventive effect of hIg in two mouse models of CIPN, induced by vincristine (VCR, 100 µg/kg/d) and oxaliplatin (OXP, 6 mg/kg/3d). Human Ig were administered one day before the first injection of chemotherapy. The onset of CIPN and effects of hIg were assessed via functional tests and morphological analyses of sensory nerves. To evaluate the effect of hIg on chemotherapy cytotoxicity, viability assays were performed using hIg (0 to 12 mg/mL) combined with anticancer agents on human cancer cell lines. The preventive treatment with hIg alleviated tactile hypersensitivity and nerve injuries induced by VCR. It also alleviated tactile/cold hypersensitivities and nerve injuries induced by OXP. Treatment with hIg did not affect the cytotoxicity of either chemotherapy. Furthermore, in combination with VCR, hIg potentiated chemo-induced cell death. In conclusion, hIg is a promising therapy to prevent the onset of CIPN and potentiate chemotherapy effect on cancer, reinforcing the interest in hIg in the management of CIPN.

show abstract

“…Involvement of the renin-angiotensin system. Bouchenaki et al 69 Thalidomide po, 10.5 mg/kg/d, 2 weeks SD rats Sciatic nerve degeneration.…”

Section: Swiss Micementioning

confidence: 99%

Animal models of chemotherapy‐induced peripheral neuropathy for hematological malignancies: A review

Mao

Cao

et al. 2022

Ibrain

View full text Add to dashboard Cite

Chemotherapy is one of the main treatments for hematologic malignancies.However, chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common long-term toxic reactions in chemotherapy, and the occurrence of CIPN affects patients' quality of life and can cause interruption of chemotherapy in severe cases, thus reducing the efficacy of chemotherapy. We currently summarize the existing CIPN animal models, including the characteristics of several common animal models such as bortezomibinduced peripheral neuropathy, vincristine-induced peripheral neuropathy, and oxaliplatin-induced peripheral neuropathy. It was found that CIPN may lead to behavioral, histopathological, and neurophysiological changes inducing peripheral neuropathy. However, the mechanism of CIPN has not been fully elucidated, especially the prevention and treatment protocols need to be improved. Therefore, this review article summarizes the progress of research on CIPN animal models and the possible mechanisms and treatment of CIPN.

show abstract

Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice

Cited by 9 publications

References 60 publications

Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice

Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice

Neuroprotective Effect of Polyvalent Immunoglobulins on Mouse Models of Chemotherapy-Induced Peripheral Neuropathy

Animal models of chemotherapy‐induced peripheral neuropathy for hematological malignancies: A review

Contact Info

Product

Resources

About